10 Year Financial Data of Biomarin Pharmaceutical, Inc. (BMRN)

64.01 (1y: +70%)

Market Cap	8.97 B	P/E(ttm)
Enterprise Value	8.67 B	P/B	7.90

BMRN- NAS (USA)
Biomarin Pharmaceutical, Inc.

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$64.01

1 Severe Warning Sign 3 Medium Warning Signs

Bookmark

Annual Rates (per share)	10 yrs*	5 yrs*	12 months*
Revenue Growth (%)	44.6	9.9	4.8
EBITDA Growth (%)	0	0	0
Free Cash Flow Growth (%)	-19.2	22.1	0
Book Value Growth (%)	0	35.9	45.6

*12-month growth rate is calculated with the per share revenue (EBITDA, FCF, earnings) of the last 12 months over the per share revenue (EBITDA, FCF, earnings) over the previous 12 months. 5-year and 10-year growth rates are calculated with least-square regression based on the 5-year and 10-year numbers.

Trendline:

Export:

Print This Table Print

See this page for the explanation of the data and charts * All numbers are in millions except for per share data

Per Share Data	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue per Share ($)	0.19	0.29	0.37	1.00	1.27	2.86	3.24	2.99	3.94	4.16	4.15	1.01	1.05	1.04	1.06	1.00
EBITDA per Share	-1.07	-2.58	-0.79	-0.15	-0.59	0.55	0.37	0.23	0.02	-0.54	-0.61	-0.10	-0.17	0.01	-0.28	-0.17
Free Cashflow per Share	-1.30	-1.39	-0.95	-0.88	-0.59	-0.63	-0.02	-0.24	-1.21	-0.22	-0.46	-0.12	-0.09	-0.01	-0.02	-0.34
Earnings per Share ($)	-1.22	-2.91	-1.08	-0.34	-0.16	0.29	--	1.73	-0.48	-0.95	-1.05	-0.21	-0.27	-0.04	-0.43	-0.31
Book Value per Share	1.90	-1.06	-1.13	1.39	1.96	2.67	3.21	5.71	6.89	8.45	9.77	6.71	8.48	8.22	8.15	9.77
Month End Stock Price	7.76	6.39	10.78	16.39	35.40	17.80	18.81	26.93	34.38	49.20	62.26	34.25	39.58	40.26	49.20	62.26
Ratios	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Return on Equity %	-64.30	--	--	-24.20	-8.40	11.10	-0.20	28.70	-7.00	-11.30	-12.80	-12.40	-12.80	-2.00	-20.80	-12.80
Return on Assets %	-29.60	-80.50	-38.00	-6.20	-1.90	3.40	-0.10	16.30	-4.10	-7.10	-10.00	-7.20	-8.40	-1.20	-13.20	-10.00
Return on Capital - Joel Greenblatt %	-243	-347	-218	-40.10	-71.40	16.30	5.70	0.10	-7.50	-25.60	-28.80	-19.60	-27.60	-9.20	-43.60	-28.80
Debt to Equity	1.06	-3.98	-2.90	1.96	2.68	2.05	1.54	0.53	0.45	0.34	0.09	0.45	0.35	0.34	0.34	0.09

Gross Margin %	100.00	78.80	89.80	89.60	84.90	82.30	79.70	81.30	81.00	81.70	84.00	85.30	81.00	80.80	79.90	84.00
Operating Margin %	-627	-962	-250	-29.30	-47.10	13.40	5.10	0.10	-7.70	-22.00	-25.70	-18.70	-25.00	-8.20	-35.60	-25.70
Net Margin %	-626	-1,006	-289	-33.90	-13.00	10.40	-0.20	54.70	-12.20	-22.80	-31.10	-20.60	-25.80	-4.20	-40.20	-31.10

Days Sales Outstanding	--	79.20	83.30	63.60	51.00	66.80	82.70	91.10	91.70	79.50	85.60	82.60	73.90	83.30	75.20	85.60
Days Inventory	--	214	1,513	1,047	645	509	436	570	565	512	603	660	464	447	441	603
Inventory Turnover	--	1.70	0.20	0.30	0.60	0.70	0.80	0.60	0.60	0.70	0.20	0.10	0.20	0.20	0.20	0.20

Debt to Revenue	10.33	14.53	8.74	2.74	4.14	1.92	1.53	1.00	0.79	0.70	0.86	2.99	2.81	2.72	2.64	0.86
COGS to Revenue	--	0.21	0.10	0.10	0.15	0.18	0.20	0.19	0.19	0.18	0.16	0.15	0.19	0.19	0.20	0.16
Inventory to Revenue	--	0.12	0.43	0.30	0.27	0.25	0.24	0.29	0.30	0.26	1.06	1.06	0.97	0.94	0.98	1.06
Interest Exp. to Revenue %	-4.73	-43.34	-39.18	-4.58	9.61	-0.00	-2.77	-1.65	-1.23	-1.01	-0.79	-1.24	-1.12	-0.83	-0.88	-0.79

Asset Turnover	0.05	0.08	0.13	0.18	0.15	0.33	0.35	0.30	0.34	0.31	0.08	0.09	0.08	0.08	0.08	0.08
Buyback Ratio	124	1.00	10.50	493	96.30	--	--	--	--	206	--	-40.70	778	-508	--	--
Income Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue	12.10	18.64	25.67	84.21	122	296	325	376	441	501	512	117	124	128	132	128
Cost of Goods Sold	--	3.95	2.63	8.74	18.36	52.51	65.91	70.29	84.02	91.83	95.23	17.11	23.57	24.62	26.53	20.50
Gross Profit	12.10	14.69	23.04	75.47	103	244	259	306	357	409	417	99.54	100	103	105	107

Selling, General, &Admin. Expense	14.40	37.61	41.56	49.03	77.54	107	124	152	175	198	204	45.25	51.54	46.34	55.05	51.05
Research &Development	54.81	49.78	56.39	66.74	78.60	93.29	115	147	214	302	312	73.83	77.81	66.21	84.36	83.74
Earnings Before DDA	-66.36	-166	-54.14	-12.72	-56.20	57.39	37.40	28.28	2.20	-64.92	-75.01	-11.27	-19.78	1.18	-35.05	-21.36

Depreciation, Depletion and Amortization	9.44	13.28	10.08	11.96	1.09	17.63	20.98	27.74	36.09	45.30	46.26	10.60	11.17	11.67	11.86	11.56

Operating Income	-75.80	-179	-64.21	-24.67	-57.29	39.76	16.43	0.54	-33.89	-110	-121	-21.87	-30.95	-10.49	-46.90	-32.92
Interest Income/Expense	-0.57	-8.08	-10.06	-3.86	11.69	-0.01	-9.00	-6.22	-5.42	-5.06	-4.62	-1.44	-1.39	-1.06	-1.17	-1.01
Net Income	-75.80	-187	-74.27	-28.53	-15.80	30.83	-0.49	206	-53.84	-114	-130	-23.97	-32.01	-5.36	-53.01	-39.81

Earnings per Share ($)	-1.22	-2.91	-1.08	-0.34	-0.16	0.29	--	1.73	-0.48	-0.95	-1.05	-0.21	-0.27	-0.04	-0.43	-0.31
Total Shares Outstanding	62.13	64.35	68.83	84.58	95.88	104	100	126	112	120	128	115	118	123	125	128
Balance Sheet	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Cash and cash equivalents	206	48.82	47.79	289	586	560	301	274	195	451	402	233	403	426	451	402
Accounts Receivable	--	4.05	5.86	14.67	16.98	54.30	73.54	93.88	111	109	120	106	101	117	109	120
Inventory	--	2.32	10.90	25.08	32.45	73.16	78.66	110	130	129	136	124	120	121	129	136
Other Current Assets	18.91	30.10	4.39	5.63	9.28	50.44	14.85	26.57	33.66	54.96	64.98	50.52	58.07	54.82	54.96	64.98
Total Current Assets	225	85.28	68.94	334	644	738	468	504	470	743	723	513	682	719	743	723

Property, Plant and Equipment	25.15	42.50	37.32	55.47	76.82	125	199	222	269	284	282	264	267	274	284	282
Intangible Assets	--	61.50	36.56	32.92	30.86	28.89	64.70	157	232	215	227	222	220	399	215	227
Other Long Term Assets	5.92	43.68	52.48	40.83	63.31	15.13	186	379	333	359	366	297	364	175	359	366
Total Assets	256	233	195	463	815	907	917	1,263	1,304	1,602	1,598	1,297	1,533	1,567	1,602	1,598

Accounts Payable	10.10	25.35	18.76	28.54	48.13	58.85	78.07	80.58	93.93	147	144	96.36	95.45	110	147	144
Current Portion of Long-Term Debt	--	42.81	11.34	6.79	6.31	70.74	--	--	--	23.37	--	23.46	23.44	23.44	23.37	--
Other Current Liabilities	2.72	1.90	10.27	10.72	7.11	0.49	0.09	3.27	0.19	-0.00	--	--	1.11	1.08	-0.00	--
Total Current Liabilities	12.82	70.05	40.37	46.05	61.54	130	78.15	83.84	94.13	170	144	120	120	135	170	144

Long-Term Debt	125	228	213	224	497	497	497	378	348	325	110	325	325	325	325	110
Other Long-Term Liabilities	0.67	2.85	19.48	75.65	68.64	2.86	19.74	84.00	88.18	90.59	94.28	80.45	87.24	92.39	90.59	94.28
Total Liabilities	138	301	273	346	628	630	595	545	531	586	348	525	532	552	586	348

Common Stock	0.06	0.07	0.08	0.09	0.10	0.10	0.10	0.11	0.12	0.13	0.14	0.12	0.12	0.12	0.13	0.14
Retained Earnings	-301	-489	-563	-592	-607	-577	-577	-371	-425	-539	-579	-449	-481	-486	-539	-579
Additional Paid-In Capital	414	421	486	709	795	853	900	1,090	1,197	1,562	1,834	1,222	1,483	1,506	1,562	1,834
Treasury Stock	--	--	--	--	--	--	--	-1.97	-3.94	-6.60	-5.72	--	--	-6.60	-6.60	-5.72
Total Equity	118	-67.98	-77.46	118	188	277	322	717	773	1,016	1,250	772	1,000	1,015	1,016	1,250
Cashflow Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Net Income	-76.38	-187	-74.27	-28.53	-15.80	30.83	-0.49	206	-53.84	-114	-130	-23.97	-32.01	-5.36	-53.01	-39.81
Depreciation, Depletion and Amortization	9.44	13.28	10.08	11.96	1.09	17.63	20.98	27.74	36.09	45.30	46.26	10.60	11.17	11.67	11.86	11.56
Cash Flow from Others	-7.87	109	1.52	-33.52	-19.78	-57.64	67.25	-215	36.50	86.66	76.68	6.20	19.41	7.90	53.14	-3.78
Cash Flow from Operations	-74.80	-65.14	-62.68	-50.09	-34.50	-9.18	87.73	18.75	18.75	17.61	-7.25	-7.17	-1.42	14.21	11.99	-32.03

Investment for Property, Plant & Equipement	-5.98	-24.08	-2.96	-24.58	-22.41	-56.37	-89.80	-49.46	-154	-44.57	-50.22	-6.18	-9.48	-15.01	-13.90	-11.83
Cash Flow from Acquisitions	--	-14.79	--	--	--	--	-8.37	-32.95	--	--	-9.88	--	--	-1.26	1.26	-9.88
Cash Flow from Investing	-50.95	-15.29	57.60	-195	-151	-19.08	-79.68	-101	-89.56	-196	-234	30.04	-152	-20.95	-52.35	-7.94

Net Issuance of Stock	94.59	1.81	7.78	141	15.22	--	--	--	--	235	222	-9.76	249	-27.23	--	--
Net Issuance of Debt	118	-29.71	22.31	146	309	-6.59	-73.79	-30.14	-5.01	-5.08	-15.35	-0.25	-0.14	-0.14	-4.55	-10.52
Other Financing	0.48	0.00	--	9.35	-0.00	29.40	10.00	33.64	34.01	81.88	106	23.45	0.07	37.68	44.11	24.34
Cash Flow from Financing	213	-27.89	30.09	296	325	22.81	-63.79	3.50	29.00	312	313	13.45	249	10.31	39.56	13.82

Net Change in Cash	87.77	-108	25.01	51.07	139	-5.44	-55.73	-79.09	-41.81	134	71.79	36.31	95.17	3.57	-0.80	-26.15

Free Cash Flow	-80.77	-89.22	-65.64	-74.67	-56.91	-65.54	-2.07	-30.72	-135	-26.96	-57.47	-13.35	-10.90	-0.80	-1.91	-43.86
Valuation Ratios (Daily)	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

PE Ratio(ttm)
Price to Tangible Book
PS Ratio
EV-to-Revenue
EV-to-EBITDA
EV-to-EBIT
Earnings Yield (Joel Greenblatt)
Forward Rate of Return
Shiller PE Ratio
Valuation and Quality	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Market Cap
Enterprise Value
Month End Stock Price
Net Cash (per share)
Net Current Asset Value (per share)
DCF (per share)
Median PS (per share)
Peter Lynch Fair Value (per share)
Graham Number (per share)
Altman Z-Score
Piotroski F-Score
Beneish M-Score

Switch to Another Stock:

BMRN Quarterly/Annuals Reports

BMRN: 10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer): (10-Q) - 2012-10-29
BMRN: 10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer): (10-Q) - 2012-04-30
BMRN: 10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer): (10-Q) - 2011-10-31
BMRN: 10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer): (10-Q) - 2011-08-01
BMRN: 10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer): (10-Q) - 2011-04-29

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Email Alerts Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

FocusBar

Home

Premium Membership

Value Screens

Model Portfolios

Guru Stocks

Market Valuation

By Country

Articles

Submit Articles

BMRN Quarterly/Annuals Reports